A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-03 and is reviewed periodically as new material appears.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
=== Diseases === Medical conditions associated with weight gain include hypothyroidism, Cushing's syndrome, Polycystic Ovary Syndrome (PCOS), and congestive heart failure. Medical conditions such as cancer, gastrointestinal illness, psychiatric disorders, infections, endocrine disorders, and neurologic disorders may lead to weight loss.
== Purpose == The protein manufacturing cost remains high and there is a growing demand to develop cost efficient and rapid protein purification methods. Understanding the different protein purification methods and optimizing the downstream processing is critical to minimize production costs while maintaining the quality of acceptable standards of homogeneity. Protein purification is either preparative or analytical. Preparative purifications aim to produce a relatively large quantity of purified proteins for subsequent use. Examples include the preparation of commercial products such as enzymes (e.g. lactase), nutritional proteins (e.g. soy protein isolate), and certain biopharmaceuticals (e.g. insulin). Several preparative purification steps are often deployed to remove bi-products, such as host cell proteins, which pose a potential threat to the patient's health. Analytical purification produces a relatively small amount of a protein for a variety of research or analytical purposes, including identification, quantification, and studies of the protein's structure, post-translational modifications, and function. Each step of a protein purification scheme is monitored and takes into consideration purification levels and yield. A high purification level and a poor yield leaves hardly any protein with which to experiment. On the other hand, a high yield with low purification levels leaves many contaminants (proteins other than the one interest) which interfere with research purposes.
activation peptide (1–37) β-sandwich (38–184) catalytic domain (185–515), in which the residues C314, H373, D396 and W279 partake in catalysis β-barrel 1 (516–628) β-barrel 2 (629–731) B units are glycoproteins. Each has a mass of about 80 kDa (8.5% of the mass is from carbohydrates), 641 residues and 10 sushi domains. Each domain has about 60 residues and 2 internal disulfide bonds.
Sources: en.wikipedia.org
== Recent research == Recent research has been directed towards finding better treatment options. Multi-drug therapy using insulin sensitizers, such as metformin and pioglitazone, has been linked to improving residual insulin action. High doses of insulin-like growth factor 1 has also been effective in patients with Rabson–Mendenhall syndrome. Though there is no cure, researchers remain optimistic on finding a cure.
Medtronic plc is an Irish medical device company. The company's legal and executive headquarters are in Ireland, while its operational headquarters are in Minneapolis, Minnesota. Medtronic rebased to Ireland following its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies. It is one of the biggest medical tech companies in the world and is currently the largest medical device company in the world by revenue. The company has developed several world-first technologies since its inception, including wearable and implantable pacemakers, the implantable cardioverter-defibrillator (ICD), and remote patient monitoring systems. They also created miniaturized devices like the world's smallest pacemaker and spinal cord stimulator.
Magnetic resonance imaging (MRI) has a sensitivity of 97-100% and specificity of 94-100% in the diagnosis of aortic dissections. MRIs take up to 20–30 minutes to complete and therefore may not be suitable for use in people who are critically ill, such as those with aortic dissections. MRIs are also not available in many resource limited settings. MRIs do not expose the person to potentially harmful ionizing radiation.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.